Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Atrial fibrillation is a major cause of stroke in apneic patients: a prospective study.

Poli M, Philip P, Taillard J, Debruxelles S, Renou P, Orgogozo JM, Rouanet F, Sibon I.

Sleep Med. 2017 Feb;30:251-254. doi: 10.1016/j.sleep.2015.07.031. Epub 2016 Mar 4.

PMID:
28041720
2.

An Analysis of the Public Financial Support Eligibility Rule for French Dependent Elders with Alzheimer's Disease.

Rapp T, Lacey L, Ousset PJ, Cowppli-Bony P, Vellas B, Orgogozo JM.

Value Health. 2015 Jul;18(5):553-9. doi: 10.1016/j.jval.2015.03.1785. Epub 2015 Jun 5.

3.

Magnetisation transfer parameters and stroke outcome.

Sibon I, Tourdias T, Felix S, Asselineau J, Bracoud L, Vivot A, Rouanet F, Renou P, Orgogozo JM, Dousset V.

J Clin Neurosci. 2015 Jun;22(6):1012-7. doi: 10.1016/j.jocn.2014.11.035. Epub 2015 Apr 16.

PMID:
25891892
4.

Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review.

Jekel K, Damian M, Wattmo C, Hausner L, Bullock R, Connelly PJ, Dubois B, Eriksdotter M, Ewers M, Graessel E, Kramberger MG, Law E, Mecocci P, Molinuevo JL, Nygård L, Olde-Rikkert MG, Orgogozo JM, Pasquier F, Peres K, Salmon E, Sikkes SA, Sobow T, Spiegel R, Tsolaki M, Winblad B, Frölich L.

Alzheimers Res Ther. 2015 Mar 18;7(1):17. doi: 10.1186/s13195-015-0099-0. eCollection 2015.

5.

Change in leisure and social activities and risk of dementia in elderly cohort.

Foubert-Samier A, Le Goff M, Helmer C, Pérès K, Orgogozo JM, Barberger-Gateau P, Amieva H, Dartigues JF.

J Nutr Health Aging. 2014 Dec;18(10):876-82. doi: 10.1007/s12603-014-0475-7.

PMID:
25470802
6.

The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.

Bocchetta M, Galluzzi S, Kehoe PG, Aguera E, Bernabei R, Bullock R, Ceccaldi M, Dartigues JF, de Mendonça A, Didic M, Eriksdotter M, Félician O, Frölich L, Gertz HJ, Hallikainen M, Hasselbalch SG, Hausner L, Heuser I, Jessen F, Jones RW, Kurz A, Lawlor B, Lleo A, Martinez-Lage P, Mecocci P, Mehrabian S, Monsch A, Nobili F, Nordberg A, Rikkert MO, Orgogozo JM, Pasquier F, Peters O, Salmon E, Sánchez-Castellano C, Santana I, Sarazin M, Traykov L, Tsolaki M, Visser PJ, Wallin ÅK, Wilcock G, Wilkinson D, Wolf H, Yener G, Zekry D, Frisoni GB.

Alzheimers Dement. 2015 Feb;11(2):195-206.e1. doi: 10.1016/j.jalz.2014.06.006. Epub 2014 Aug 20.

PMID:
25150733
7.

Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty.

Robert PH, König A, Amieva H, Andrieu S, Bremond F, Bullock R, Ceccaldi M, Dubois B, Gauthier S, Kenigsberg PA, Nave S, Orgogozo JM, Piano J, Benoit M, Touchon J, Vellas B, Yesavage J, Manera V.

Front Aging Neurosci. 2014 Mar 24;6:54. doi: 10.3389/fnagi.2014.00054. eCollection 2014.

8.

Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.

Amieva H, Mokri H, Le Goff M, Meillon C, Jacqmin-Gadda H, Foubert-Samier A, Orgogozo JM, Stern Y, Dartigues JF.

Brain. 2014 Apr;137(Pt 4):1167-75. doi: 10.1093/brain/awu035. Epub 2014 Feb 27.

PMID:
24578544
9.

Playing board games, cognitive decline and dementia: a French population-based cohort study.

Dartigues JF, Foubert-Samier A, Le Goff M, Viltard M, Amieva H, Orgogozo JM, Barberger-Gateau P, Helmer C.

BMJ Open. 2013 Aug 29;3(8):e002998. doi: 10.1136/bmjopen-2013-002998.

10.

A simple score to predict survival with dementia in the general population.

Delva F, Pimouguet C, Helmer C, Péres K, Bréchat B, Le Goff M, Jacqmin-Gadda H, Amieva H, Orgogozo JM, Auriacombe S, Berr C, Tzourio C, Barberger-Gateau P, Dartigues JF.

Neuroepidemiology. 2013;41(1):20-8. doi: 10.1159/000346497. Epub 2013 Mar 19.

PMID:
23548733
11.

Short- versus long-term prediction of dementia among subjects with low and high educational levels.

Chary E, Amieva H, Pérès K, Orgogozo JM, Dartigues JF, Jacqmin-Gadda H.

Alzheimers Dement. 2013 Sep;9(5):562-71. doi: 10.1016/j.jalz.2012.05.2188. Epub 2012 Nov 14.

PMID:
23159045
12.

[Paquid 2012: illustration and overview].

Dartigues JF, Helmer C, Letenneur L, Péres K, Amieva H, Auriacombe S, Orgogozo JM, Commenges D, Jacqmin-Gadda H, Richard-Harston S, Delva F, Foubert-Samier A, Barberger-Gateau P.

Geriatr Psychol Neuropsychiatr Vieil. 2012 Sep;10(3):325-31. Review. French.

PMID:
23015241
13.

Prediction of subacute infarct size in acute middle cerebral artery stroke: comparison of perfusion-weighted imaging and apparent diffusion coefficient maps.

Drier A, Tourdias T, Attal Y, Sibon I, Mutlu G, Lehéricy S, Samson Y, Chiras J, Dormont D, Orgogozo JM, Dousset V, Rosso C.

Radiology. 2012 Nov;265(2):511-7. doi: 10.1148/radiol.12112430. Epub 2012 Aug 24.

PMID:
22923715
14.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.

PMID:
22677258
15.

Assessment of quality of life in stroke patients with hemiplegia.

Laurent K, De Sèze MP, Delleci C, Koleck M, Dehail P, Orgogozo JM, Mazaux JM.

Ann Phys Rehabil Med. 2011 Sep;54(6):376-90. doi: 10.1016/j.rehab.2011.06.002. Epub 2011 Aug 5. English, French.

16.

Gender differences in the prodromal signs of dementia: memory complaint and IADL-restriction. a prospective population-based cohort.

Pérès K, Helmer C, Amieva H, Matharan F, Carcaillon L, Jacqmin-Gadda H, Auriacombe S, Orgogozo JM, Barberger-Gateau P, Dartigues JF.

J Alzheimers Dis. 2011;27(1):39-47. doi: 10.3233/JAD-2011-110428.

PMID:
21725162
17.

Final cerebral infarct volume is predictable by MR imaging at 1 week.

Tourdias T, Renou P, Sibon I, Asselineau J, Bracoud L, Dumoulin M, Rouanet F, Orgogozo JM, Dousset V.

AJNR Am J Neuroradiol. 2011 Feb;32(2):352-8. doi: 10.3174/ajnr.A2271. Epub 2010 Oct 21.

18.

Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Leuner K, Kurz C, Guidetti G, Orgogozo JM, Müller WE.

Front Neurosci. 2010 Sep 7;4. pii: 44. doi: 10.3389/fnins.2010.00044. eCollection 2010.

19.

Normal cerebrovascular reactivity in Stroke-like Migraine Attacks after Radiation Therapy syndrome.

Farid K, Meissner WG, Samier-Foubert A, Barret O, Menegon P, Rouanet F, Fernandez P, Orgogozo JM, Allard M, Tison F, Sibon I.

Clin Nucl Med. 2010 Aug;35(8):583-5. doi: 10.1097/RLU.0b013e3181e4db6f.

PMID:
20631504
20.

Stroke in under-75-year-olds: expectations, concerns and needs.

Jerome D, Dehail P, Daviet JC, Lamothe G, De Sèze MP, Orgogozo JM, Mazaux JM.

Ann Phys Rehabil Med. 2009 Sep-Oct;52(7-8):525-37. doi: 10.1016/j.rehab.2009.06.007. Epub 2009 Aug 19. English, French.

21.

Use of the Triage Stroke Panel in a neurologic emergency service.

Sibon I, Rouanet F, Meissner W, Orgogozo JM.

Am J Emerg Med. 2009 Jun;27(5):558-62. doi: 10.1016/j.ajem.2008.05.001.

PMID:
19497461
22.

Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.

Grossberg G, Sadowsky C, Fröstl H, Frölich L, Nagel J, Tekin S, Zechner S, Ros J, Orgogozo JM.

Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):158-64.

PMID:
19484917
23.

Inter- and intraobserver reliability of five MRI sequences in the evaluation of the final volume of cerebral infarct.

Sibon I, Ménégon P, Orgogozo JM, Asselineau J, Rouanet F, Renou P, Tourdias T, Pachai C, Chêne G, Dousset V.

J Magn Reson Imaging. 2009 Jun;29(6):1280-4. doi: 10.1002/jmri.21779.

PMID:
19472382
24.

What we have learned from the Xaliproden Sanofi-aventis trials.

Douillet P, Orgogozo JM.

J Nutr Health Aging. 2009 Apr;13(4):365-6. No abstract available.

PMID:
19300882
25.

Methodological issues in primary prevention trials for neurodegenerative dementia.

Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B.

J Alzheimers Dis. 2009;16(2):235-70. doi: 10.3233/JAD-2009-0971. Review.

PMID:
19221415
26.

Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.

Amieva H, Le Goff M, Millet X, Orgogozo JM, Pérès K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF.

Ann Neurol. 2008 Nov;64(5):492-8. doi: 10.1002/ana.21509.

PMID:
19067364
27.

Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study.

Letenneur L, Pérès K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF.

PLoS One. 2008;3(11):e3637. doi: 10.1371/journal.pone.0003637. Epub 2008 Nov 4.

28.

Gender and education impact on brain aging: a general cognitive factor approach.

Proust-Lima C, Amieva H, Letenneur L, Orgogozo JM, Jacqmin-Gadda H, Dartigues JF.

Psychol Aging. 2008 Sep;23(3):608-620. doi: 10.1037/a0012838.

PMID:
18808250
29.

[Anti-amyloid immunotherapy in Alzheimer's disease].

Orgogozo JM.

Rev Neurol (Paris). 2008 Apr;164 Spec No 2:F95-7. Review. French. No abstract available.

PMID:
18680825
30.

[Update on vascular dementias].

Auriacombe S, Amarenco P, Baron JC, Ceccaldi M, Dartigues JF, Lehéricy S, Hénon H, Hinaut P, Orgogozo JM; Groupe de consensus Théma.

Rev Neurol (Paris). 2008 Jan;164(1):22-41. doi: 10.1016/j.neurol.2007.06.001. Epub 2008 Feb 20. Review. French.

PMID:
18342055
31.

Early prevention at public health issue.

Dartigues JF, Helmer C, Peres K, Cowppli Bony P, Auriacombe S, Orgogozo JM.

J Nutr Health Aging. 2008 Jan;12(1):84S-5S. Review.

PMID:
18165852
32.

Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study.

Pérès K, Helmer C, Amieva H, Orgogozo JM, Rouch I, Dartigues JF, Barberger-Gateau P.

J Am Geriatr Soc. 2008 Jan;56(1):37-44. Epub 2007 Nov 20.

PMID:
18028344
33.

Magnetization transfer imaging shows tissue abnormalities in the reversible penumbra.

Tourdias T, Dousset V, Sibon I, Pele E, Menegon P, Asselineau J, Pachai C, Rouanet F, Robinson P, Chene G, Orgogozo JM.

Stroke. 2007 Dec;38(12):3165-71. Epub 2007 Oct 25.

PMID:
17962607
34.

COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke.

Sibon I, Coupry I, Menegon P, Bouchet JP, Gorry P, Burgelin I, Calvas P, Orignac I, Dousset V, Lacombe D, Orgogozo JM, Arveiler B, Goizet C.

Ann Neurol. 2007 Aug;62(2):177-84.

PMID:
17696175
35.

Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.

Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK.

Neurology. 2007 Jul 24;69(4 Suppl 1):S23-8.

PMID:
17646620
36.

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.

Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R.

Lancet Neurol. 2007 Jun;6(6):501-12. Erratum in: Lancet Neurol. 2007 Oct;6(10):849.

PMID:
17509485
37.

Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community.

Carcaillon L, Pérès K, Péré JJ, Helmer C, Orgogozo JM, Dartigues JF.

Dement Geriatr Cogn Disord. 2007;23(6):439-45. Epub 2007 Apr 26.

38.

MRI versus CT in acute stroke.

Meissner W, Sibon I, Rouanet F, Ménégon P, Orgogozo JM.

Lancet. 2007 Apr 21;369(9570):1342. doi: 10.1016/S0140-6736(07)60623-0. No abstract available.

PMID:
17448810
39.

Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.

Helmer C, Andrieu S, Pérès K, Orgogozo JM, Vellas B, Dartigues JF; REAL.fr Group.

Dement Geriatr Cogn Disord. 2007;23(3):168-74. Epub 2007 Jan 11.

PMID:
17215578
40.

Third Asia-pacific regional meeting of the international working group on harmonization of dementia drug guidelines: meeting report summary.

Senanarong V, Chen CP, Orgogozo JM; Program Committee.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):311-2.

PMID:
17132979
41.

Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.

Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM; ESTAT investigators.

Lancet. 2006 Nov 25;368(9550):1871-8.

PMID:
17126719
42.

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.

Burns A, O'Brien J; BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology.

J Psychopharmacol. 2006 Nov;20(6):732-55. Review.

PMID:
17060346
43.

Restriction in complex activities of daily living in MCI: impact on outcome.

Pérès K, Chrysostome V, Fabrigoule C, Orgogozo JM, Dartigues JF, Barberger-Gateau P.

Neurology. 2006 Aug 8;67(3):461-6.

PMID:
16894108
44.

Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity.

Helmer C, Pérès K, Letenneur L, Guttiérez-Robledo LM, Ramaroson H, Barberger-Gateau P, Fabrigoule C, Orgogozo JM, Dartigues JF.

Dement Geriatr Cogn Disord. 2006;22(1):87-94. Epub 2006 May 18.

PMID:
16710088
45.

[Vascular risk factors and Alzheimer disease risk: epidemiological studies review].

Cowppli-Bony P, Dartigues JF, Orgogozo JM.

Psychol Neuropsychiatr Vieil. 2006 Mar;4(1):47-60. Review. French.

46.

Marchiafava-Bignami disease: diffusion-weighted MRI in corpus callosum and cortical lesions.

Ménégon P, Sibon I, Pachai C, Orgogozo JM, Dousset V.

Neurology. 2005 Aug 9;65(3):475-7.

PMID:
16087921
47.

Creutzfeldt-Jakob disease mimicking radiologic posterior reversible leukoencephalopathy.

Sibon I, Foubert A, Menegon P, Yekhlef F, Dousset V, Orgogozo JM.

Neurology. 2005 Jul 26;65(2):329. No abstract available.

PMID:
16043814
48.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team.

Neurology. 2005 May 10;64(9):1553-62.

PMID:
15883316
49.

The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study.

Amieva H, Jacqmin-Gadda H, Orgogozo JM, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF.

Brain. 2005 May;128(Pt 5):1093-101. Epub 2005 Mar 17.

PMID:
15774508
50.

[Stroke-like presentation of cerebral lymphoma].

Sibon I, Yekhlef F, Vital A, Orgogozo JM.

Rev Neurol (Paris). 2005 Jan;161(1):74-7. French.

PMID:
15678004

Supplemental Content

Loading ...
Support Center